Impact of baseline body mass index on the outcomes of patients with neuroendocrine neoplasms

Abdel‐Rahman, Omar; Ghosh, Sunita; Morrish, Don

doi:10.1007/s40618-022-01805-7

Cited by 7 publications

(15 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, this analysis shows that obesity may have a protective effect against NET severity [ 157 ]. Similar conclusions were drawn on the basis of the assessment of the impact of baseline BMI (at the stage of disease diagnosis) on the treatment outcomes of patients with NEN and it has been proven that higher BMI is associated with better overall survival among patients with NEN [ 158 ]. These analyzes were carried out on the basis of the combined administrative databases of one of the provinces of Canada from 2004–2019, reviewing patients with NEN and data on the BMI of patients at the time of diagnosis of NET [ 158 ].…”

Section: Obesity and Its Comorbidities And The Risk Of Gep-netssupporting

confidence: 62%

“…Similar conclusions were drawn on the basis of the assessment of the impact of baseline BMI (at the stage of disease diagnosis) on the treatment outcomes of patients with NEN and it has been proven that higher BMI is associated with better overall survival among patients with NEN [ 158 ]. These analyzes were carried out on the basis of the combined administrative databases of one of the provinces of Canada from 2004–2019, reviewing patients with NEN and data on the BMI of patients at the time of diagnosis of NET [ 158 ]. Interestingly, Pareira et al [ 159 ] found the presence of IL-6 in the peritumoral stroma of the intestine and pancreas (mainly in fibroblasts, endothelium, and immune cells), but there were not statistically significant differences between GI-NET patients with MetS and without MetS.…”

Section: Obesity and Its Comorbidities And The Risk Of Gep-netssupporting

confidence: 62%

See 1 more Smart Citation

Inflammation Related to Obesity in the Etiopathogenesis of Gastroenteropancreatic Neuroendocrine Neoplasms

et al. 2022

View full text Add to dashboard Cite

Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are rare neoplasms, which, due to their heterogeneous nature, non-specific symptoms, and lack of specific tumor markers pose many diagnostic and clinical challenges. In recent years, the effectiveness of GEP-NEN diagnosis has increased, which is probably associated with the greater availability of diagnostic tests and the cooperation of many experienced specialists in various scientific disciplines. In addition to the possible genetic etiology, the cause of GEP-NET development is not fully understood. Inflammation and obesity are known risks that contribute to the development of many diseases. Chronic inflammation accompanying obesity affects the hormonal balance and cell proliferation and causes the impairment of the immune system function, leading to neoplastic transformation. This review explores the role of inflammation and obesity in GEP-NETs. The exact mechanisms inducing tumor growth are unknown; however, the profile of inflammatory factors released in the GEP-NET tumor microenvironment is responsible for the progression or inhibition of tumor growth. Both the excess of adipose tissue and the impaired function of the immune system affect not only the initiation of cancer but also reduce the comfort and lifetime of patients.

show abstract

Section: Obesity and Its Comorbidities And The Risk Of Gep-netssupporting

confidence: 62%

Section: Obesity and Its Comorbidities And The Risk Of Gep-netssupporting

confidence: 62%

Inflammation Related to Obesity in the Etiopathogenesis of Gastroenteropancreatic Neuroendocrine Neoplasms

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Overall, the TNM stage remains a critical prognostic factor. [47][48][49][50][51][52][53][54] When investigating the prognostic factors of g-NEC and g-MiNEN, we found that postoperative adjuvant therapy can extend the OS of patients with g-NEC and g-MiNEN, and it emerges as an independent prognostic factor of g-NEC. We classified postoperative adjuvant therapy into categories such as adjuvant chemotherapy, adjuvant radiotherapy, and immunotherapy.…”

Section: Discussionmentioning

confidence: 84%

“…Other studies have reported diverse prognostic factors. Overall, the TNM stage remains a critical prognostic factor 47–54 …”

Section: Discussionmentioning

confidence: 99%

Clinicopathological characteristics of gastric neuroendocrine neoplasms: A comprehensive analysis

Zi,

Ma,

Chen

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

ObjectiveThis study aimed to explore the clinicopathological characteristics and prognostic implications of gastric neuroendocrine neoplasms (g‐NENs).MethodsA retrospective enrollment of 142 patients diagnosed with g‐NENs was conducted at Zhejiang Cancer Hospital between January 1, 2007 and December 31, 2021. The study compared essential clinicopathological features and survival rates. Additionally, the prognosis of gastric neuroendocrine carcinomas/mixed neuroendocrine–non‐neuroendocrine neoplasms (g‐NEC/MiNEN) were contrasted with those of gastric adenocarcinoma (GAC) and signet ring cell carcinoma (SRCC).ResultsThe study comprised a total of 142 g‐NENs cases, with a male‐to‐female ratio of approximately 2:1. The 5‐year survival rates for g‐NEC and g‐MiNEN were 26.7% and 35.2%, respectively. Corresponding 5‐year survival rates for G1 and G2 were observed at 100% and 80.0%, respectively. g‐NEC/MiNEN showed a significantly worse prognosis compared to g‐NET (p < 0.001). g‐NEC/MiNEN exhibited a poor prognosis compared to GAC (p < 0.001), and within poorly differentiated GAC, g‐NEC/MiNEN demonstrated a worse prognosis (p = 0.007). Additionally, patients receiving postoperative adjuvant therapy exhibited notably prolonged overall survival (OS) in the case of g‐NEC/MiNEN (p = 0.010).ConclusionIn short, the prognosis of g‐NEC/MiNEN was worse than that of g‐NET, GAC and poorly differentiated GAC, but this group benefit from postoperative adjuvant therapy.

show abstract

“…Obesity has been proved to be associated with the development of many chronic disease such as cardiovascular disease, type 2 diabetes, non‐alcoholic fatty liver disease, nephropathy and retinopathy 21–23 . In contrast, obese patients have also been reported to show better clinical prognosis in various cancers than their underweight counterparts 24–26 . This phenomenon is known as the obesity paradox.…”

Section: Discussionmentioning

confidence: 99%

Increased adipose tissue is associated with improved overall survival, independent of skeletal muscle mass in non‐small cell lung cancer

Tao,

Fang,

Chen

et al. 2023

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

BackgroundThe prognostic significance of non‐cancer‐related prognostic factors, such as body composition, has gained extensive attention in oncological research. Compared with sarcopenia, the prognostic significance of adipose tissue for overall survival in non‐small cell lung cancer remains unclear. We investigated the prognostic value of skeletal muscle and adipose tissue in patients with non‐small cell lung cancer.MethodsThis retrospective study included 4434 patients diagnosed with non‐small cell lung cancer between January 2014 and December 2016. Cross‐sectional areas of skeletal muscle and subcutaneous fat were measured, and the pericardial fat volume was automatically calculated. The skeletal muscle index and subcutaneous fat index were calculated as skeletal muscle area and subcutaneous fat area divided by height squared, respectively, and the pericardial fat index was calculated as pericardial fat volume divided by body surface area. The association between body composition and outcomes was evaluated using Cox proportional hazards model.ResultsA total of 750 patients (501 males [66.8%] and 249 females [33.2%]; mean age, 60.9 ± 9.8 years) were included. Sarcopenia (60.8% vs. 52.7%; P < 0.001), decreased subcutaneous fat index (51.4% vs. 25.2%; P < 0.001) and decreased pericardial fat index (55.4% vs. 16.5%; P < 0.001) were more commonly found in the deceased group than survived group. In multivariable Cox regression analysis, after adjusting for clinical variables, increased subcutaneous fat index (hazard ratio [HR] = 0.56, 95% confidence interval [CI]: 0.47–0.66, P < 0.001) and increased pericardial fat index (HR = 0.47, 95% CI: 0.40–0.56, P < 0.001) were associated with longer overall survival. For stage I–III patients, increased subcutaneous fat index (HR = 0.62, 95% CI: 0.48–0.76, P < 0.001) and increased pericardial fat index (HR = 0.43, 95% CI: 0.34–0.54, P < 0.001) were associated with better 5‐year overall survival rate. Similar results were recorded in stage IV patients. For patients with surgery, the prognostic value of increased subcutaneous fat index (HR = 0.60, 95% CI: 0.44–0.80, P = 0.001) and increased pericardial fat index (HR = 0.51, 95% CI: 0.38–0.68, P < 0.001) remained and predicted favourable overall survival. Non‐surgical patients showed similar results as surgical patients. No association was noted between sarcopenia and overall survival (P > 0.05).ConclusionsIncreased subcutaneous fat index and pericardial fat index were associated with a higher 5‐year overall survival rate, independent of sarcopenia, in non‐small cell lung cancer and may indicate a reduced risk of non‐cancer‐related death.

show abstract

Impact of baseline body mass index on the outcomes of patients with neuroendocrine neoplasms

Cited by 7 publications

References 22 publications

Inflammation Related to Obesity in the Etiopathogenesis of Gastroenteropancreatic Neuroendocrine Neoplasms

Inflammation Related to Obesity in the Etiopathogenesis of Gastroenteropancreatic Neuroendocrine Neoplasms

Clinicopathological characteristics of gastric neuroendocrine neoplasms: A comprehensive analysis

Increased adipose tissue is associated with improved overall survival, independent of skeletal muscle mass in non‐small cell lung cancer

Contact Info

Product

Resources

About